



COLLABORATIVE STAGE  
DATA COLLECTION SYSTEM

## Skin Malignancies

Education & Training Team  
Collaborative Stage Data Collection System  
Version 2.01

---

---

---

---

---

---

---

---



COLLABORATIVE STAGE  
DATA COLLECTION SYSTEM

## Merkel Cell Carcinoma

---

---

---

---

---

---

---

---

## Learning Objectives

- Understand Merkel cell carcinoma
- Learn the CS codes
- Learn the site specific factors
- Able to correctly abstract and stage a Merkel cell carcinoma patient's chart



---

---

---

---

---

---

---

---

## Overview

- CS Tumor Size and Extension
- CS Lymph Nodes
- CS Mets at Dx
- Site Specific Factors

4



---

---

---

---

---

---

---

---

## Merkel Cell Carcinoma

- What is it?
  - A rare aggressive type of skin cancer
- Incidence
  - 1200 new cases annually

5



---

---

---

---

---

---

---

---

## MCC Presentation

- Presentation
  - Usually a firm painless lump that resembles a cyst, but is fixed
  - It can be red, pink or blue-violet
  - It grows rapidly

6



---

---

---

---

---

---

---

---

## Merkel Cell Carcinoma



Image courtesy of Paul Nghiem, MD, PhD

7



---

---

---

---

---

---

---

---

## Merkel Cell Carcinoma



• Image courtesy of Paul Nghiem, MD, PhD

8



---

---

---

---

---

---

---

---

## MCC Risk Factors

- Age >65
- Caucasian
- Prolonged sun exposure
- Arsenic exposure
- Immunosuppression
- Ultraviolet-A light (PUVA)

9



---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

- ### MCC Pathology
- 3 subtypes
    - Intermediate (most common)
    - Small cell
    - Trabecular (least common)
- Image courtesy of Paul Nghiem, MD, PhD
- 11

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

### Small Cell Type of MCC




Image courtesy of Paul Nghiem, MD, PhD

13



---

---

---

---

---

---

---

---

### Trabecular Type of MCC




Image courtesy of Paul Nghiem, MD, PhD

14



---

---

---

---

---

---

---

---

### MCC Treatment

- Wide excision with 1 to 2.5 cm margins
  - Depending on site
- Sentinel node biopsy
  - If nodes are not palpable
- Bx of palpable lymph nodes & lymphadenectomy
- Radiotherapy
  - Primary site
  - Draining lymph node basin

15



---

---

---

---

---

---

---

---

### CS Tumor Size

- 000 No mass found
- 001-988 001-988 mm, code exact size
- 989 989 mm or larger
- 990 Microinvasion; micro focus or foci only, no size of focus given
- 991 Described as <1 cm
- 992-996 Inexact size special codes

16



---

---

---

---

---

---

---

---

### CS Tumor Size

- 992 <2 cm but >1 cm OR between 1-2 cm OR Stated as T1 with no other info on size
- 993 <3 cm but >2 cm OR between 2-3 cm
- 994 <4 cm but >3 cm OR between 3-4 cm
- 995 <5 cm but >4 cm OR between 4-5 cm OR Stated as T2 with no other info on size
- 996 >5 cm or stated as T3 with no other info on size

17



---

---

---

---

---

---

---

---

### CS Extension

- 000 In situ, non-invasive
- 100 Confined to dermis
- 400 Localized NOS
- 500 Sub Q tissue - through the entire dermis

18



---

---

---

---

---

---

---

---

### CS Extension

- 600 Stated as T1
- 610 Stated as T2
- 620 Stated as T3
- 700 Underlying cartilage, bone, skeletal muscle, fascia
- 800 Further contiguous extension
- 950 No evidence of primary tumor

19



---

---

---

---

---

---

---

---

### CS Tumor Size/Extension Eval

- Unchanged from standard table

20



---

---

---

---

---

---

---

---

### CS Lymph Nodes

- 000 No regional node involvement
- 100 Regional nodes by primary site
- 200 Head and neck nodes
- 300 Code 100 + 200
- 320 Stated at N1a with no other information
- 340 Stated as N1b with no other information

21



---

---

---

---

---

---

---

---

### CS Lymph Nodes

- 360 Stated as N1 NOS
- 400 In-transit met WITHOUT nodal met or involvement of nodes not stated
- 420 In-transit met WITH nodes in code 100
- 440 In-transit met WITH nodes in code 200
- 800 Lymph nodes NOS
- 999 Unknown; not stated

22



---

---

---

---

---

---

---

---

### CS Lymph Node Eval

- New rules for AJCC 7<sup>th</sup> Edition necessitated changes

23



---

---

---

---

---

---

---

---

### MX Eliminated

- MX has been eliminated from 7<sup>th</sup> Edition
  - Clinical M0
  - Unless clinical or pathologic evidence of mets
- cM only requires history and physical
- Infer cM0 unless known cM1

24



---

---

---

---

---

---

---

---



### CS Mets at Dx

- 00 None
- 10 Distant node(s)
- 15 Mets to skin or subQ tissue
- 20 Stated as M1a with no other information
- 30 Lung
- 35 30 + 10 or 15
- 37 Stated as M1b with no other information

25



---

---

---

---

---

---

---

---

### CS Mets at Dx

- 40 All other visceral sites. Carcinomatosis.  
Distant mets except as listed before
- 52 40 + any of 10, 15 or 30
- 55 Stated as M1c with no other information
- 60 Distant mets NOS  
Stated as M1 NOS
- 99 Unknown

26



---

---

---

---

---

---

---

---

### CS Mets Eval

- Unchanged from standard table

27



---

---

---

---

---

---

---

---

### Mets at Dx-Metastatic Sites

- 4 new fields
  - Bone excluding marrow
  - Lung excluding pleura and pleural fluid
  - Brain excluding spinal cord and other CNS
  - Liver
- Code 0 when CS Mets at Dx is 00
- Code structure
  - 0 – No
  - 1 – Yes
  - 8 – Not applicable
  - 9 – Unknown

28



---

---

---

---

---

---

---

---

### SSF1 Measured Thickness (Depth)

- Code exact size in TENTHS of mm
- 001-979 00.1 – 97.9 mm
- 980 98 mm or larger
- 998 No histologic exam of primary site
- 990 Microinvasion; microscopic focus or foci only, and no size given

29



---

---

---

---

---

---

---

---

### SSF 3 Clinical Assessment Positive Nodes

- 000 No nodal mets or in-transit mets WITHOUT regional node involvement
- 010 Clinically occult nodes only (micromets)
- 020 Clinically apparent nodal mets (macromets)
- 999 Unknown, not stated, not documented in chart

30



---

---

---

---

---

---

---

---

### SSF 16 Size of Mets in Nodes

- Record largest mets in node in hundredths of mm
- 001-979 0.01 – 9.79 mm
- 980 9.80 mm or larger
- 990 Mets or tumor nests in regional nodes, size cannot be assessed
- 998 No histologic exam of primary site

31



---

---

---

---

---

---

---

---

### SSF 17 Path Nodal Extracapsular Extension

- 010 No extracapsular extension clinically AND extracapsular extension present on pathology
- 020 No extracapsular extension clinically AND not present or not stated on pathology
- 030 No extracapsular extension clinically AND nodes not assessed pathologically

32



---

---

---

---

---

---

---

---

### SSF 17 Path Nodal Extracapsular Extension

- 040 Extracapsular extension clinically AND extracapsular extension on path
- 050 Extracapsular extension clinically AND not present or not stated on path
- 060 Extracapsular extension clinically AND nodes not assessed pathologically

33



---

---

---

---

---

---

---

---

### SSF 17 Path Nodal Extracapsular Extension

- 070 Extracapsular extension clinically unknown AND extracapsular extension present on path
- 080 Extracapsular extension clinically unknown AND extracapsular extension not present or not stated on path
- 090 Extracapsular extension clinically unknown AND nodes not assessed pathologically

34




---

---

---

---

---

---

---

---

### SSF 17 TABLE

CODE	Clinical Extracapsular Extension	Pathologic Extracapsular Extension
010	Neg	Pos
020	Neg	Neg/not stated
030	Neg	Not assessed
040	Pos	Pos
050	Pos	Neg/not stated
060	Pos	Not assessed
070	Unknown	Pos
080	Unknown	Neg/not stated
090	Unknown	Not assessed

35




---

---

---

---

---

---

---

---

### SSF 18 Isolated Tumor Cells (ITC) in Nodes

- 000 Negative on H&E, ITC not present by IHC, unknown if tested by IHC. Nodes clinically negative, not examined pathologically. IHC stains used are CK20, CAM5.2, pancytokeratins
- 010 Nodes negative on H&E and IHC and ITCs not present
- 020 Nodes negative on H&E , + on IHC, and ITCs are present

36




---

---

---

---

---

---

---

---

### SSF 18 Isolated Tumor Cells (ITCs) in Nodes

- 090 Regional nodes negative on H&E, positive for tumor detected by IHC, size of tumor cells not stated
- 100 Regional nodes positive with ITCs on H&E
- 200 Regional nodes positive with ITCs NOS method of detection not stated
- 300 Regional nodes positive other than ITCs (tumor cells > 0.2 mm)

37



---

---

---

---

---

---

---

---

### SSF19 Tumor Transection Status

- 000 No mass/tumor found
- 010 Tumor base transected
- 020 Tumor base not transected
- 998 No histologic exam of primary site
- 999 Unknown, not documented in chart

38



---

---

---

---

---

---

---

---

### SSF20 Tumor Infiltrating Lymphocytes (TIL)

- TIL in the primary tumor
  - Special cancer-fighting cells of immune system
  - Level of infiltrates at base of vertical growth phase
- 010 TIL present, non-brisk
- 020 TIL present, brisk
- 030 TIL present NOS
- 998 No histologic specimen

39



---

---

---

---

---

---

---

---

### SSF 21 Growth Pattern of Primary Tumor

- 010 Circumscribed/nodular
- 020 Diffusely infiltrative
- 030 Sample inadequate to evaluate or comment as stated the path report

40



---

---

---

---

---

---

---

---

### SSF 22 Profound Immunosuppression

- 000 No immune suppression conditions
- 010 HIV/AIDS
- 020 Solid organ transplant recipient
- 030 CLL

41



---

---

---

---

---

---

---

---

### SSF 22 Profound Immunosuppression

- 040 Non-Hodgkin lymphoma
- 050 More than one of the above
- 060 Other specified diagnosis resulting in profound immunosuppression
- 070 Profound immunosuppression present, diagnosis not recorded

42



---

---

---

---

---

---

---

---

## Merkel Cell Carcinoma

- A rare but aggressive tumor
- Incidence is increasing
- Specific stains to determine the diagnosis
- Clinical lymph node status an important prognostic factor

43



---

---

---

---

---

---

---

---



COLLABORATIVE STAGE  
DATA COLLECTION SYSTEM

## Melanoma

---

---

---

---

---

---

---

---

## Learning Objectives

- Learn the differences between CSv1 and CSv2
- Be able to correctly abstract and stage a melanoma patient's chart

45



---

---

---

---

---

---

---

---

### Overview

- Changes from CSv1 to CSv2
- CS Tumor Size and Extension
- CS Lymph Nodes
- CS Mets at Dx
- Site Specific Factors

46



---

---

---

---

---

---

---

---

### CS Tumor Size

- 001-988 001-988 mm (exact size in mm)
- 989 989 mm or larger
- 990 Micro focus or foci, no size of focus given
- 991 Described as <1 cm
- 992 <2 cm or >1 cm or between 1-2 cm  
T1 NOS with no documentation of tumor size

47



---

---

---

---

---

---

---

---

### CS Tumor Size

- 993 <3 cm or >2 cm or between 2-3 cm  
T2 NOS with no documentation of tumor size
- 994 <4 cm or >3 cm or between 3-4 cm
- 995 <5 cm or >4 cm or between 4-5 cm
- CS Tumor Size Eval unchanged

48



---

---

---

---

---

---

---

---



### CS Extension

- 000 In situ, non-invasive, intradermal, Clark level I
- 100 Papillary dermis invaded, Clark level II
- 200 Papillary-reticular dermal interface invaded, Clark level III
- 300 Reticular dermis invaded, Clark level IV
- 400 Skin/dermis NOS, Localized NOS
- 500 SubQ tissue invaded, Clark level V

49



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

### CS Extension

- 800 Further contiguous extension, Underlying cartilage, bone, skeletal muscle
- 950 No evidence of primary tumor
- 999 Unknown extension, Primary tumor cannot be assessed (e.g. shave biopsy or regressed melanoma)
- CS Tumor Size/Extension Eval unchanged

51



---

---

---

---

---

---

---

---

## CS Lymph Nodes

- 100 Regional nodes by primary site
- 120 Head and neck nodes
- 130 Satellite nodules or in-transit mets NOS (distance from primary site not stated) WITHOUT regional node involvement or regional node involvement not stated

52



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---

## CS Lymph Nodes

- 140 Satellite nodule(s) or in-transit mets  $\leq 2$  cm from primary WITHOUT regional node involvement or node involvement not stated
- 150 Satellite nodule(s) or in-transit mets  $>2$  cm from primary WITHOUT regional node involvement or involvement not stated

54



---

---

---

---

---

---

---

---

### CS Lymph Nodes

- 170 Matted nodes in code 100
- 180 Matted nodes in code 120
- 200 Satellite nodule(s) or in-transit mets WITH regional nodes in code 100
- 220 Satellite nodule(s) or in-transit mets WITH regional nodes in code 120
- 800 Lymph nodes NOS

55



---

---

---

---

---

---

---

---

### MX Eliminated

- MX has been eliminated from 7<sup>th</sup> Edition
  - Clinical M0
  - Unless clinical or pathologic evidence of mets
- cM only requires history and physical
- Infer cM0 unless known cM1

56



---

---

---

---

---

---

---

---

### CS Mets at Dx

- 05 Underlying cartilage, bone, skeletal muscle
- 10 Distant lymph nodes
- 40 Distant metastasis NOS
- 42 Mets to skin or subQ tissue beyond regional nodes
- 43 Lung

57



---

---

---

---

---

---

---

---

### CS Mets at Dx

- 44 All other visceral sites  
Carcinomatosis  
Other distant sites
- 52 10 + 42
- 53 10 + 43
- 54 10 + 44

58



---

---

---

---

---

---

---

---

### Mets at Dx-Metastatic Sites

- 4 new fields
  - Bone excluding marrow
  - Lung excluding pleura and pleural fluid
  - Brain excluding spinal cord and other CNS
  - Liver
- Code 0 when CS Mets at Dx is 00
- Code structure
  - 0 – No
  - 1 – Yes
  - 8 – Not applicable
  - 9 – Unknown

59



---

---

---

---

---

---

---

---

### SSF1-3 Unchanged

- SSF1 Depth of Invasion
  - Code exact size in hundredths of mm
- SSF2 Ulceration
  - No mention of ulceration in path report – assume no ulceration
- SSF3 Clinical Status of Lymph Node Mets
  - Code 000 No lymph node mets OR
  - Code 000 Satellite lesion or in-transit mets without nodes

60



---

---

---

---

---

---

---

---

### SSF4 LDH

- 000 Test not done
- 002 Within normal limits
- 004 Range1 1.5 x normal limit OR elevated NOS
- 005 Range 2 1.5 – 10 x normal limit
- 006 Range 3 more than 10 normal limit
- 008 Test ordered, results not in chart

61



---

---

---

---

---

---

---

---

### SSF5 LDH Value

- Code value of LDH
  - Prior to treatment or within 6 weeks of diagnosis
  - Give priority to the earliest tests performed
- Code value from same test used in SSF 4
- Record actual value for values 001 through 800
- Record range for values 801 and greater
  - Codes 801 – 825 are ranges in intervals of 20
  - Codes 826 – 863 are ranges in intervals of 50
  - Codes 864 - 921 are ranges in intervals of 100
  - Code 922 is a value of 10001 or greater

62



---

---

---

---

---

---

---

---

### SSF5 LDH Value

- | Code  | Description                                   |
|-------|---|
| • 060 | Actual value of 60                            |
| • 801 | Value 801 to 820                              |
| • 864 | Value 3201 to 3300                            |
| • 899 | Value 7701 to 7800                            |
| • 922 | Value is 10001 or greater                     |
| • 995 | Stated as within normal limits, no other info |
| • 996 | Stated as elevated, no other info             |
| • 997 | Test ordered, results not in chart            |
| • 998 | Test not done                                 |

63



---

---

---

---

---

---

---

---

### SSF6 LDH Upper Limits of Normal

- Record upper limits of normal for LDH
- Upper limit of normal varies based on the lab
- 001-979 Upper limit of normal is 001-979
- 997 Upper limit of normal not in chart
- 998 Test not done
- 999 Unknown, no documentation

64



---

---

---

---

---

---

---

---

### SSF7 Primary Tumor Mitotic Count/Rate

- 000 Mitotic rate <1 per millimeter squared
- 001-010 1-10 per millimeter squared
- 011 11 millimeter squared or greater
- 998 No histologic exam of primary site
- 999 Unknown, not stated, not documented

65



---

---

---

---

---

---

---

---

### SSF8 Primary Tumor Regression

- Not identified should be coded as absent
- 000 No regression  
Regression not identified  
Regression absent
- 001 Regression present
- 999 Unknown, not stated, not documented

66



---

---

---

---

---


---

---

---

### SSF9 Vertical Growth Phase

- Not identified should be coded as absent
- 000 No vertical growth phase present  
Vertical growth phase not identified  
Vertical growth phase absent
- 001 Vertical growth phase present
- 999 Unknown, not stated, not documented

67 

---

---

---

---

---


---

---

---

### Melanoma

- Addition of 5 new site specific factors
- T category is now based on
  - Depth of invasion
  - Ulceration
  - Mitotic rate

68 

---

---

---

---

---


---

---


---

### Inquiry & Response System

- Submit questions to Inquiry & Response System
  - Allows tracking for educational purposes
  - Provides information for all



- <http://web.facs.org/coc/default.htm>

69 

---

---

---

---

---

---

---

---

American Joint Committee on Cancer  
Contact Information

Karen A. Pollitt – Manager

email: [kpollitt@facs.org](mailto:kpollitt@facs.org)

phone: 312-202-5313

Donna M. Gress, RHIT, CTR – Technical Specialist

email: [dgress@facs.org](mailto:dgress@facs.org)

phone: 312-202-5410

General Inquiries can be directed to [AJCC@facs.org](mailto:AJCC@facs.org)

AJCC Web Site

<sup>70</sup> [www.cancerstaging.org](http://www.cancerstaging.org)



---

---

---

---

---

---

---

---